Shorter Two-Drug Blood Thinner Treatment After Minor Stroke Guided by Platelet Testing
Compares 7 versus 21 days of aspirin plus clopidogrel after minor stroke.
Plain-language title generated from the registry record
Registry title: Platelet Aggregation Function-Guided De-Escalation Antiplatelet Therapy in Patients With Acute Ischemic Stroke
Key facts
- Where
- Chengdu, ChinaSee the site
- Phase
- Phase 4
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who had a minor ischemic stroke or a high-risk transient ischemic attack within the last 48 hours and whose blood tests show they respond well to clopidogrel.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Acute non-disabling ischemic stroke (NIHSS score of 5 or lower) or high-risk transient ischemic attack (ABCD2 score of 4 or higher). Symptoms started within 48 hours.
- Earlier treatment
- Must have received clopidogrel 300 mg and aspirin 100 mg within 48 hours of symptom onset. Must not have used heparin or oral anticoagulants within 10 days, or antiplatelet drugs other than aspirin or clopidogrel (such as ticagrelor or prasugrel) within 7 days.
- Biomarker or test result
- MARADP below 35%, measured 5 to 20 hours after clopidogrel 300 mg plus aspirin 100 mg.
Main reasons for not taking part
- Bleeding in the brain, or another brain disease such as a tumor or multiple sclerosis
- Atrial fibrillation or another clear reason to take anticoagulants
- Clot-busting treatment or thrombectomy after the event, or planned within 90 days
- History of gut bleeding, brain bleeding or serious recent bleeding
- Pregnant or breastfeeding women, or allergy or intolerance to clopidogrel or aspirin
Read by machine on 9 November 2026.
Where in China
- Sichuan Provincial People's HospitalChengdu, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Sichuan Provincial People's Hospital
- Trial code
- NCT07644234
- Record updated
- 12 June 2026
- Original description
This multicenter, prospective, open-label, randomized controlled trial will evaluate whether platelet aggregation function-guided de-escalation of antiplatelet therapy is non-inferior in efficacy and superior in safety compared with standard dual antiplatelet therapy in patients with acute minor ischemic stroke or high-risk transient ischemic attack who are sensitive to clopidogrel.Read full original descriptionShow less
Platelet Aggregation Function-Guided De-Escalation Antiplatelet Therapy in Patients With Acute Ischemic Stroke
This multicenter, prospective, open-label, randomized controlled trial will evaluate whether platelet aggregation function-guided de-escalation of antiplatelet therapy is non-inferior in efficacy and superior in safety compared with standard dual antiplatelet therapy in patients with acute minor ischemic stroke or high-risk transient ischemic attack who are sensitive to clopidogrel.
Participants who present within 48 hours of symptom onset and meet the eligibility criteria will receive loading doses of clopidogrel and aspirin, followed by platelet aggregation function testing. Eligible clopidogrel-sensitive participants will be randomized to receive either 7 days of dual antiplatelet therapy followed by clopidogrel monotherapy or standard 21-day dual antiplatelet therapy followed by single antiplatelet therapy. The primary efficacy outcome is new stroke within 90 days after randomization.
Inclusion: 1.Age 18 years or older. 2.Diagnosis of acute non-disabling ischemic stroke or transient ischemic attack according to World Health Organization criteria, meeting one of the following definitions: acute non-disabling ischemic stroke, defined as a National Institutes of Health Stroke Scale score of 5 or lower at enrollment; or high-risk transient ischemic attack, defined as an ABCD2 score of 4 or higher; 3.Symptom onset within 48 hours. Onset time is defined as the interval from the last time the participant was known to be well to the time of combined administration of clopidogrel 300 mg and aspirin 100 mg; 4.MARADP <35% measured 5 to 20 hours after combined antiplatelet treatment with clopidogrel 300 mg and aspirin 100 mg within 48 hours of symptom onset; 5.Planned treatment with aspirin plus clopidogrel or clopidogrel monotherapy for antiplatelet therapy; 6.Written informed consent provided by the participant or a legally authorized representative.
Exclusion: 6.Use of antiplatelet agents other than aspirin or clopidogrel within 7 days before enrollment, such as ticagrelor or prasugrel; 10.Use of heparin or oral anticoagulants within 10 days before enrollment. 11.Severe cardiac, pulmonary, hepatic, or renal dysfunction, or severe comorbid disease such as tumor, chronic airflow disease, severe dementia, or severe heart failure; 2.Minor stroke or transient ischemic attack caused by angioplasty or vascular surgery; 3.Atrial fibrillation indicated by standard electrocardiography or typical physical signs of atrial fibrillation, including absolutely irregular rhythm, variable intensity of the first heart sound, or pulse deficit; 4.A clear indication for anticoagulation, including suspected cardioembolism such as atrial fibrillation, known artificial heart valve, or suspected endocarditis; 7.History of gastrointestinal bleeding, intracranial hemorrhage, recent major bleeding or blood transfusion, excluding minor hemoptysis or minor abnormal vaginal bleeding, or other bleeding disorder caused by coagulation dysfunction, such as purpura; 8.Contraindication or intolerance to clopidogrel or aspirin, including known allergy; severe hepatic insufficiency or renal insufficiency; severe heart failure; coagulation disorder or history of systemic bleeding; history of thrombocytopenia or neutropenia; or history of drug-induced hematologic disease or hepatic dysfunction; 9.Leukopenia, defined as white blood cell count <2 x 10\^9/L, or thrombocytopenia, defined as platelet count <100 x 10\^9/L; 5.Intravenous thrombolysis, intra-arterial thrombolysis, mechanical thrombectomy, or any revascularization procedure performed after the index event or planned within 90 days; 12.Female participants of childbearing potential with a negative pregnancy test who refuse to use effective contraception, or women who are pregnant or breastfeeding; 13.Poor compliance or inability to complete study requirements; -.